Molecular and clinical features of patients with progressive and stable CLL included in the training and validation sets
| Samples Characteristics . | FTP . | LTP . | No. of patients with therapy needed . | IGHV homology ≥ 98%, no. of patients . | IGHV homology < 98%, no. of patients . | ZAP-70–positive cells ≥ 20%, no. of patients . | ZAP-70–positive cells < 20%, no. of patients . |
|---|---|---|---|---|---|---|---|
| Training set | |||||||
| Progressive CLL (N = 23) | 18 | 10 | 13 | 8 | 15 | ||
| Median β2m level | 2 | 2.7 | |||||
| Median WBC count | 48.7 | 136.5 | |||||
| Stable CLL (N = 13) | 0 | 3 | 10 | 3 | 10 | ||
| Median β2m level | 1.8 | 1.6 | |||||
| Median WBC count | 26.4 | 30.9 | |||||
| Validation set | |||||||
| Progressive CLL (N = 30) | 27 | 18 | 12 | 17 | 13 | ||
| Median β2m level | 1.7 | 2.5 | |||||
| Median WBC count | 25.6 | 48 | |||||
| Stable CLL (N = 48) | 0 | 6 | 42 | 12 | 36 | ||
| Median β2m level | 1.8 | 1.9 | |||||
| Median WBC count | 19.4 | 20.2 |
| Samples Characteristics . | FTP . | LTP . | No. of patients with therapy needed . | IGHV homology ≥ 98%, no. of patients . | IGHV homology < 98%, no. of patients . | ZAP-70–positive cells ≥ 20%, no. of patients . | ZAP-70–positive cells < 20%, no. of patients . |
|---|---|---|---|---|---|---|---|
| Training set | |||||||
| Progressive CLL (N = 23) | 18 | 10 | 13 | 8 | 15 | ||
| Median β2m level | 2 | 2.7 | |||||
| Median WBC count | 48.7 | 136.5 | |||||
| Stable CLL (N = 13) | 0 | 3 | 10 | 3 | 10 | ||
| Median β2m level | 1.8 | 1.6 | |||||
| Median WBC count | 26.4 | 30.9 | |||||
| Validation set | |||||||
| Progressive CLL (N = 30) | 27 | 18 | 12 | 17 | 13 | ||
| Median β2m level | 1.7 | 2.5 | |||||
| Median WBC count | 25.6 | 48 | |||||
| Stable CLL (N = 48) | 0 | 6 | 42 | 12 | 36 | ||
| Median β2m level | 1.8 | 1.9 | |||||
| Median WBC count | 19.4 | 20.2 |
FTP indicates first time point; LTP, last time point; β2m, β2 microglobulin; and WBC, white blood cell.